The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy
Indian Journal of Cancer · 2025
DOI: 10.4103/ijc.ijc_894_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2025. Verfasst von Ramya D Ravi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, St John's Medical College, Bengaluru, Karnataka, India. Hauptthemen laut MEDLINE: CA-125 Antigen, Peritoneal Neoplasms, Omentum, Ovarian Neoplasms. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To assess the role of omental and ovarian chemotherapy response score (CRS) and CA125 as a predictor of prognosis in patients with tubo-ovarian high-grade serous carcinoma (HGSC)/primary peritoneal carcinoma (PPC) receiving neoadjuvant chemotherapy (NACT). In addition, to study the correlation of omental CRS with chemoresistance.
Methods
A retrospective record review of patients with tubo-ovarian HGSC/PPC receiving NACT followed by interval debulking surgery (IDS) between January 2012 and May 2020 was done. The slides of the omentum and ovarian tissue of the patients were retrieved and reviewed by a trained pathologist. During analysis, CRS 1 and CRS 2 were merged together for comparison against CRS 3.
Results
A total of 44 patients with a mean age of 54 years were included in the study. Among the patients, 29.5%, 38.6%, and 31.8% had a CRS of 1, 2, and 3, respectively, on the omental specimen and 31.8%, 43.2%, and 25% on the ovarian specimen. Median PFS and OS was significantly better with omental CRS 3 ( P = < 0.0001 and P = < 0.00065). No significant difference in median OS of patients was noted with ovarian CRS 1, 2, or 3 ( P = 0.057); however, the median PFS was significantly better in patients with CRS 3 on ovarian tissue ( P = 0.036). Platinum resistance was significantly lower in patients with CRS 3 on omentum ( P = 0.001). The value of CA125 post NACT had a significant association with PFS on both univariate and multivariate analyses. There was no statistically significant correlation between CA125 and omental CRS.
Conclusion
Omental CRS has a prognostic significance for patients with tubo-ovarian HGSC/PPC receiving NACT and correlates significantly with PFS and OS. Ovarian CRS correlates significantly only with PFS. Post NACT CA125 value had a significant association with PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, St John's Medical College, Bengaluru, Karnataka, India.
- Department of Pathology, St John's Medical College, Bengaluru, Karnataka, India.
ORCID-Profile: Ramya D Ravi, Kiran A Kulkarni, Geeta Acharya, Premalatha Siddharta, Gayatri Ravikumar, Vishakha C Bidkar, D Mohanapriya
Zitieren
APA
Ravi, R. D., Kulkarni, K. A., Acharya, G., Siddharta, P., Ravikumar, G., Bidkar, V. C., & Mohanapriya, D. (2025). The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_894_21
Vancouver
Ravi RD, Kulkarni KA, Acharya G, Siddharta P, Ravikumar G, Bidkar VC, et al. The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy. Indian Journal of Cancer. 2025. doi:10.4103/ijc.ijc_894_21
BibTeX
@article{Ravi2025,
author = {Ravi, Ramya D and Kulkarni, Kiran A and Acharya, Geeta and Siddharta, Premalatha and Ravikumar, Gayatri and Bidkar, Vishakha C and Mohanapriya, D},
title = {The prognostic role of omental, ovarian chemotherapy response score and CA125 in predicting survival in patients with tubo-ovarian high-grade serous carcinoma/primary peritoneal carcinoma receiving neoadjuvant chemotherapy},
journal = {Indian Journal of Cancer},
year = {2025},
doi = {10.4103/ijc.ijc_894_21}
}
EUVIMED